BioStem Technologies showcases expanded perinatal tissue portfolio at SAWC Spring 2026, featuring Neox Product line and clinical evidence for advanced wound careBioStem Technologies showcases expanded perinatal tissue portfolio at SAWC Spring 2026, featuring Neox Product line and clinical evidence for advanced wound care

BioStem Technologies to Present Expanded Product Portfolio and Clinical Data at Major Wound Care Symposium

2026/04/08 19:03
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

BioStem Technologies announced its participation in the Symposium on Advanced Wound Care Spring meeting in Charlotte, NC, from April 8-12, 2026. The company will highlight its recently introduced Neox Product line, which expands its capabilities across multiple tissue formats and provides physicians with differentiated options depending on clinical needs. According to Chairman and CEO Jason Matuszewski, this addition reinforces the company’s focus on advancing science and equipping clinicians with data and tools to improve patient outcomes.

The company’s expanded portfolio offers what it describes as the most comprehensive suite of placental and umbilical cord tissue solutions, backed extensively by both randomized clinical trials and real-world evidence. BioStem will host a lunch symposium titled ‘A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence’ on Thursday, April 9th, featuring presentations by Dr. Wendy Weston, William Marston, MD, and Herbert Slade, MD. The session will include discussion of the newly expanded product portfolio, the science behind its birth tissue products, recently published results of a randomized controlled trial on diabetic foot ulcers, and practical guidance on incorporating these therapies into clinical practice.

BioStem will also present a new scientific poster presentation available for viewing in Exhibit Hall 1C, demonstrating its continued investment in clinical research and medical education. The company’s quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks and are established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. Additional information about the company is available at https://www.biostemtechnologies.com.

The company’s participation in SAWC, one of the premier gatherings for wound care professionals, clinicians, and researchers, represents an opportunity to share clinical evidence supporting its technologies. BioStem’s portfolio of quality brands includes its Neox, Clarix, VENDAJE and American Amnion product lines, developed using proprietary BioRetain, CryoTek and SteriTek processing technologies designed to optimize preservation of natural tissue properties. The latest news and updates relating to the company are available at https://tinyurl.com/bsemnewsroom.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by PRISM Mediawire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is BioStem Technologies to Present Expanded Product Portfolio and Clinical Data at Major Wound Care Symposium.

The post BioStem Technologies to Present Expanded Product Portfolio and Clinical Data at Major Wound Care Symposium appeared first on citybuzz.

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.06463
$0.06463$0.06463
-0.85%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!